The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP

Leukemia Research

Volumn 36, Issue 4, 2012, Pages 413-417

  Castillo, Jorge J ^a   Beltran, Brady E ^b   Song, Moo Kon ^c   Ilic, Ivana ^d   Leppa, Sirpa ^e   Nurmi, Heidi ^e   Seki, Ritsuko ^f   Uccella, Silvia ^g   Li, Jun Min ^h   Treaba, Diana O ^a   Stachurski, Dariusz ^a   Butera, James N ^a  

^a BROWN UNIVERSITY   (United States)

^b HOSPITAL NACIONAL EDGARDO REBAGLIATI MARTINS   (Peru)

^c Pusan National University Hospital   (South Korea)

^d KBC Zagreb   (Croatia)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g UNIVERSITY OF INSUBRIA   (Italy)

^h SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Diffuse large B cell lymphoma; Hans algorithm; Non germinal center; Rituximab

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERFERON REGULATORY FACTOR 4; LACTATE DEHYDROGENASE; PREDNISONE; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; ASIAN; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; ECOG PERFORMANCE STATUS; ETHNIC GROUP; FEMALE; GENDER; GERMINAL CENTER; HANS ALGORITHM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

EID: 84862777067     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.12.012     Document Type: Article

References (24)

1. Stein H., Warnke R., Chan W., et al. Diffuse large B-cell lymphoma, not otherwise specified. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 233-237. IARC, Lyon, France. S. Swerdlow (Ed.).
2. Feugier P., Van Hoof A., Sebban C., et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005, 23:4117-4126.
3. Pfreundschuh M., Trumper L., Osterborg A., et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7:379-391.
4. Lenz G., Wright G., Dave S.S., et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008, 359:2313-2323.
5. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329:987-994.
6. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
7. Rosenwald A., Wright G., Chan W.C., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937-1947.
8. Hans C.P., Weisenburger D.D., Greiner T.C., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103:275-282.
9. Song M.K., Chung J.S., Seol Y.M., et al. Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy. Ann Oncol 2010, 21:140-144.
10. Seki R., Ohshima K., Fujisaki T., et al. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 2009, 100:1842-1847.
11. Ilic I., Mitrovic Z., Aurer I., et al. Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab. Int J Hematol 2009, 90:74-80.
12. Uccella S., Placidi C., Marchet S., et al. Bcl-6 protein expression, and not the germinal centre immunophenotype, predicts favourable prognosis in a series of primary nodal diffuse large B-cell lymphomas: a single centre experience. Leuk Lymphoma 2008, 49:1321-1328.
13. Nyman H., Adde M., Karjalainen-Lindsberg M.L., et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007, 109:4930-4935.
14. Xia Z.G., Xu Z.Z., Zhao W.L., et al. The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment. Ann Hematol 2010, 89:171-177.
15. Choi W.W., Weisenburger D.D., Greiner T.C., et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009, 15:5494-5502.
16. Shenoy P.J., Malik N., Nooka A., et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer 2010, [Epub ahead of print].
17. Griffiths R., Gleeson M., Knopf K., Danese M. Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL). BMC Cancer 2010, 10:625.
18. Ott G., Ziepert M., Klapper W., et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010, 116:4916-4925.
19. Meyer P.N., Fu K., Greiner T.C., et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011, 29:200-207.
20. Xia Y., Li Z.M., Shi Y.X., et al. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma. Ai Zheng 2009, 28:146-149.
21. Zinzani P.L., Broccoli A., Stefoni V., et al. Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. Cancer 2010, 116:5667-5675.
22. Fang C., Xu W., Li J.Y. A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma. Ann Hematol 2010, 89:1107-1113.
23. de Jong D., Xie W., Rosenwald A., et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol 2009, 62:128-138.
24. Winter J.N., Weller E.A., Horning S.J., et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006, 107:4207-4213.